Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the tolerability and safety of Myfortic in liver
transplant patients. Patients receiving CellCept who have GI side effects will have CellCept
discontinued and changed to Myfortic (Myfortic is a new drug similar to CellCept, except it
is enteric-coated). Our hypothesis is that Myfortic has less GI side effects and will,
therefore, be tolerated better than CellCept and also that Myfortic will have a comparable
effectiveness to CellCept.